ACTINIUM PHARMACEUTICALS, INC. Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
ACTINIUM PHARMACEUTICALS, INC. (ATNM) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $707.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-30.
Financial Statements › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2026-03-30
- ACTINIUM PHARMACEUTICALS, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2022-12-31 was $0.00.
- ACTINIUM PHARMACEUTICALS, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2022-09-30 was $0.00.
- ACTINIUM PHARMACEUTICALS, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2020-12-31 was $0.00.
- ACTINIUM PHARMACEUTICALS, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2020-09-30 was $0.00.
- ACTINIUM PHARMACEUTICALS, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2025 was $707.00K.
- ACTINIUM PHARMACEUTICALS, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2022 was $2.60M.
- ACTINIUM PHARMACEUTICALS, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2020 was $83.00K, a 89.71% decline from fiscal 2019.
- ACTINIUM PHARMACEUTICALS, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2019 was $807.00K.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month as first filed | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month as first filed | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2025-12-31 | $707.00K 10-K · filed 2026-03-30 | ||||||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $0.00 derived: sum of 2 quarters · filed 2024-03-29 | $2.60M 10-K · filed 2024-03-29 | ||||
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $2.60M 10-Q · filed 2023-11-02 | |||||
| 2022-06-30 | $2.60M 10-Q · filed 2023-08-14 | ||||||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-25 | $0.00 derived: sum of 2 quarters · filed 2022-03-25 | $0.00 derived: sum of 3 quarters · filed 2022-03-25 | $83.00K 10-K · filed 2022-03-25 | |||
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $0.00 derived: sum of 2 quarters · filed 2021-11-12 | $83.00K 10-Q · filed 2021-11-12 | -$73.00K derived: sum of 4 quarters · filed 2021-11-12 | |||
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-30 | $83.00K 10-Q · filed 2021-07-30 | -$73.00K derived: sum of 3 quarters · filed 2021-07-30 | -$287.00K derived: sum of 4 quarters · filed 2021-07-30 | |||
| 2020-03-31 | $83.00K 10-Q · filed 2021-05-14 | -$73.00K derived: sum of 2 quarters · filed 2021-05-14 | -$287.00K derived: sum of 3 quarters · filed 2021-05-14 | $748.96K derived: sum of 4 quarters · filed 2021-05-14 | |||
| 2019-12-31 | -$156.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-31 | -$370.00K derived: sum of 2 quarters · filed 2021-03-31 | $665.96K derived: sum of 3 quarters · filed 2021-03-31 | $807.00K 10-K · filed 2021-03-31 | $807.37K 10-K · filed 2020-05-08 | ||
| 2019-09-30 | -$214.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-23 | $821.96K derived: sum of 2 quarters · filed 2020-10-23 | $963.00K 10-Q · filed 2020-10-23 | $963.43K 10-Q · filed 2019-11-12 | |||
| 2019-06-30 | $1.04M 10-Q · filed 2019-08-09 | $1.18M 10-Q · filed 2020-08-14 | |||||
| 2019-03-31 | $1.18M 10-Q · filed 2020-06-29 | $1.11M 10-Q · filed 2019-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 |